A tissue engineering approach to progenitor cell delivery results in significant cell engraftment and improved myocardial remodeling

David Simpson, Hong Liu, Tai-Hwang Fan, Robert Nerem, Samuel C. Dudley

Research output: Contribution to journalArticle

145 Citations (Scopus)

Abstract

Cell replacement therapy has become an attractive solution for myocardial repair. Typical cell delivery techniques, however, suffer from poor cell engraftment and inhomogeneous cell distributions. Therefore, we assessed the hypothesis that an epicardially applied, tissue-engineered cardiac patch containing progenitor cells would result in enhanced exogenous cell engraftment. Human mesenchymal stem cells (hMSCs) were embedded into a rat tail type I collagen matrix to form the cardiac patch. Myocardial infarction was induced by left anterior descending coronary artery ligation in immunocompetent male cesarean-derived fischer rats, and patches with or without cells were secured to hearts with fibrin sealant. After patch formation, hMSCs retained a viability of >90% over 5 days in culture. In addition, >75% of hMSCs maintained a high degree of potency prior to patch implantation. After 4 days in culture, patches were applied to the epicardial surface of the infarct area and resulted in 23% ± 4% engraftment of hMSCs at 1 week (n = 6). Patch application resulted in a reduction in left ventricle interior diameter at systole, increased anterior wall thickness, and a 30% increase in fractional shortening. Despite this improvement in myocardial remodeling, hMSCs were not detectable at 4 weeks after patch application, implying that improvement did not require long-term cell engraftment. Patches devoid of progenitor cells showed no improvement in remodeling. In conclusion, pluripotent hMSCs can be efficiently delivered to a site of myocardial injury using an epicardial cardiac patch, and such delivery results in improved myocardial remodeling after infarction.

Original languageEnglish (US)
Pages (from-to)2350-2357
Number of pages8
JournalStem Cells
Volume25
Issue number9
DOIs
StatePublished - Sep 1 2007

Fingerprint

Tissue Engineering
Mesenchymal Stromal Cells
Stem Cells
Fibrin Tissue Adhesive
Systole
Inbred F344 Rats
Cell- and Tissue-Based Therapy
Collagen Type I
Infarction
Heart Ventricles
Ligation
Tail
Coronary Vessels
Myocardial Infarction
Wounds and Injuries

All Science Journal Classification (ASJC) codes

  • Molecular Medicine
  • Developmental Biology
  • Cell Biology

Cite this

A tissue engineering approach to progenitor cell delivery results in significant cell engraftment and improved myocardial remodeling. / Simpson, David; Liu, Hong; Fan, Tai-Hwang; Nerem, Robert; Dudley, Samuel C.

In: Stem Cells, Vol. 25, No. 9, 01.09.2007, p. 2350-2357.

Research output: Contribution to journalArticle

Simpson, David ; Liu, Hong ; Fan, Tai-Hwang ; Nerem, Robert ; Dudley, Samuel C. / A tissue engineering approach to progenitor cell delivery results in significant cell engraftment and improved myocardial remodeling. In: Stem Cells. 2007 ; Vol. 25, No. 9. pp. 2350-2357.
@article{4b1aafad439341ebb9978fe1d31c7c45,
title = "A tissue engineering approach to progenitor cell delivery results in significant cell engraftment and improved myocardial remodeling",
abstract = "Cell replacement therapy has become an attractive solution for myocardial repair. Typical cell delivery techniques, however, suffer from poor cell engraftment and inhomogeneous cell distributions. Therefore, we assessed the hypothesis that an epicardially applied, tissue-engineered cardiac patch containing progenitor cells would result in enhanced exogenous cell engraftment. Human mesenchymal stem cells (hMSCs) were embedded into a rat tail type I collagen matrix to form the cardiac patch. Myocardial infarction was induced by left anterior descending coronary artery ligation in immunocompetent male cesarean-derived fischer rats, and patches with or without cells were secured to hearts with fibrin sealant. After patch formation, hMSCs retained a viability of >90{\%} over 5 days in culture. In addition, >75{\%} of hMSCs maintained a high degree of potency prior to patch implantation. After 4 days in culture, patches were applied to the epicardial surface of the infarct area and resulted in 23{\%} ± 4{\%} engraftment of hMSCs at 1 week (n = 6). Patch application resulted in a reduction in left ventricle interior diameter at systole, increased anterior wall thickness, and a 30{\%} increase in fractional shortening. Despite this improvement in myocardial remodeling, hMSCs were not detectable at 4 weeks after patch application, implying that improvement did not require long-term cell engraftment. Patches devoid of progenitor cells showed no improvement in remodeling. In conclusion, pluripotent hMSCs can be efficiently delivered to a site of myocardial injury using an epicardial cardiac patch, and such delivery results in improved myocardial remodeling after infarction.",
author = "David Simpson and Hong Liu and Tai-Hwang Fan and Robert Nerem and Dudley, {Samuel C.}",
year = "2007",
month = "9",
day = "1",
doi = "10.1634/stemcells.2007-0132",
language = "English (US)",
volume = "25",
pages = "2350--2357",
journal = "Stem Cells",
issn = "1066-5099",
publisher = "AlphaMed Press",
number = "9",

}

TY - JOUR

T1 - A tissue engineering approach to progenitor cell delivery results in significant cell engraftment and improved myocardial remodeling

AU - Simpson, David

AU - Liu, Hong

AU - Fan, Tai-Hwang

AU - Nerem, Robert

AU - Dudley, Samuel C.

PY - 2007/9/1

Y1 - 2007/9/1

N2 - Cell replacement therapy has become an attractive solution for myocardial repair. Typical cell delivery techniques, however, suffer from poor cell engraftment and inhomogeneous cell distributions. Therefore, we assessed the hypothesis that an epicardially applied, tissue-engineered cardiac patch containing progenitor cells would result in enhanced exogenous cell engraftment. Human mesenchymal stem cells (hMSCs) were embedded into a rat tail type I collagen matrix to form the cardiac patch. Myocardial infarction was induced by left anterior descending coronary artery ligation in immunocompetent male cesarean-derived fischer rats, and patches with or without cells were secured to hearts with fibrin sealant. After patch formation, hMSCs retained a viability of >90% over 5 days in culture. In addition, >75% of hMSCs maintained a high degree of potency prior to patch implantation. After 4 days in culture, patches were applied to the epicardial surface of the infarct area and resulted in 23% ± 4% engraftment of hMSCs at 1 week (n = 6). Patch application resulted in a reduction in left ventricle interior diameter at systole, increased anterior wall thickness, and a 30% increase in fractional shortening. Despite this improvement in myocardial remodeling, hMSCs were not detectable at 4 weeks after patch application, implying that improvement did not require long-term cell engraftment. Patches devoid of progenitor cells showed no improvement in remodeling. In conclusion, pluripotent hMSCs can be efficiently delivered to a site of myocardial injury using an epicardial cardiac patch, and such delivery results in improved myocardial remodeling after infarction.

AB - Cell replacement therapy has become an attractive solution for myocardial repair. Typical cell delivery techniques, however, suffer from poor cell engraftment and inhomogeneous cell distributions. Therefore, we assessed the hypothesis that an epicardially applied, tissue-engineered cardiac patch containing progenitor cells would result in enhanced exogenous cell engraftment. Human mesenchymal stem cells (hMSCs) were embedded into a rat tail type I collagen matrix to form the cardiac patch. Myocardial infarction was induced by left anterior descending coronary artery ligation in immunocompetent male cesarean-derived fischer rats, and patches with or without cells were secured to hearts with fibrin sealant. After patch formation, hMSCs retained a viability of >90% over 5 days in culture. In addition, >75% of hMSCs maintained a high degree of potency prior to patch implantation. After 4 days in culture, patches were applied to the epicardial surface of the infarct area and resulted in 23% ± 4% engraftment of hMSCs at 1 week (n = 6). Patch application resulted in a reduction in left ventricle interior diameter at systole, increased anterior wall thickness, and a 30% increase in fractional shortening. Despite this improvement in myocardial remodeling, hMSCs were not detectable at 4 weeks after patch application, implying that improvement did not require long-term cell engraftment. Patches devoid of progenitor cells showed no improvement in remodeling. In conclusion, pluripotent hMSCs can be efficiently delivered to a site of myocardial injury using an epicardial cardiac patch, and such delivery results in improved myocardial remodeling after infarction.

UR - http://www.scopus.com/inward/record.url?scp=34748874691&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34748874691&partnerID=8YFLogxK

U2 - 10.1634/stemcells.2007-0132

DO - 10.1634/stemcells.2007-0132

M3 - Article

VL - 25

SP - 2350

EP - 2357

JO - Stem Cells

JF - Stem Cells

SN - 1066-5099

IS - 9

ER -